alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
LXX at another new high
According to a 2016 report by Deloitte, the legal Canadian marijuana market could soon be worth $18 billion annually. As for volume, Deloitte forecast annual demand for the plant at about 1.32 million pounds per year.
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
NetworkNewsWire Announces Publication Discussing Innovative New Delivery Platform for Cannabinoids, Tobacco and Medicine
New York, New York--(Newsfile Corp. - November 6, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids.
The publication is titled, "Bioabsorption Breakthrough Shows Promise for Tobacco, Cannabinoids, Medication." It highlights a lipophilic technology developed to address the need for enhanced bio-absorption across multiple industries.
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Thanks for the links everyone and yes Webinar was excellent. Here is the last news I do not see posted here
2017-11-02 09:03 ET - News Release
Mr. Chris Bunka reports
LEXARIA BIOSCIENCE ACQUIRES 100% OWNERSHIP OF POVIVA TEA LLC
Lexaria Bioscience Corp. has acquired 100-per-cent ownership interest in its majority-owned subsidiary Poviva Tea LLC.
Lexaria previously owned a 51-per-cent interest in Poviva Tea LLC and has acquired the remaining 49-per-cent interest. The acquisition consolidates ownership of Poviva Tea LLC as a wholly owned Lexaria Bioscience subsidiary and simplifies future operations and certain intellectual property ownership. Compensation was $70,000 (U.S.), a waiver on certain debts, and a 5-per-cent, 20-year royalty on net profits of ViPova Tea tea, coffee and hot chocolate sales. No Lexaria stock or options were issued.
"This acquisition strengthens Lexaria's intellectual property positioning and we reaffirm our commitment to the ViPova Tea product lines," said chief executive officer Chris Bunka. "Lexaria thanks the founders of Poviva Tea LLC for their assistance and vision in this transaction."
Lexaria's patented DehydraTech technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredients (APIs) substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
About Lexaria Bioscience Corp.
Lexaria has developed and outlicenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the United States and in Australia related to edible forms of cannabinoids.
November 1 @ 1:15 pm - 2:00 pm
Lexaria is in the midst of its busiest period ever: we’ve never had as many initiatives to manage at once as we do today. Perversely it is because of our hectic pace that we’ve not communicated to our growing audience of stakeholders as well as we should.
So… an update and peak behind the scenes of Lexaria Bioscience.
Save the Date: Lexaria Web-Meeting
November 1, 2017 at 1:15PM Pacific, Lexaria will hold its first ever Web-Meeting. We will deliver all our latest news and a short corporate presentation. We’re expecting to have a LOT to talk about – don’t miss this! This meeting is open to everyone but you must register first.
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
2017-10-31 16:54 ET - News Release
Mr. John Docherty reports
LEXARIA BIOSCIENCE RECEIVES GROUNDBREAKING U.S. PATENT ALLOWANCE FOR ITS DEHYDRATECH DELIVERY OF THC, NSAIDS, NICOTINE AND VITAMINS
Lexaria Bioscience Corp. has received a new notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the use of its technology as a delivery platform for all cannabinoids, including tetrahydrocannabinol; fat-soluble vitamins; non-steroidal anti-inflammatory pain medications (NSAIDs); and nicotine.
This notice of allowance applies to the delivery of all active pharmacological ingredients (APIs) Lexaria had been seeking. While Lexaria has always had confidence in its patent applications, the rapid allowance for this broad API applicability is significantly ahead of company expectations. As was true with the company's existing non-psychoactive cannabinoid patent that was granted in 2016, Lexaria expects formal patent issuance within three to four months, which is expected to provide protection until at least 2035.
Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,799, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof."
Lexaria also continues to advance all its additional patent applications in various countries as it levers patent success in the United States. For example, one of the company's patent applications has recently entered the active patent investigation phase in China.
"Issuance of this broad patent will give Lexaria the ability to ramp up our technology outlicensing activities, especially within the pharmaceutical sector where the expanded API capacity of our DehydraTech delivery platform will be most applicable," said John Docherty, president lof Lexaria.
"This wide-ranging patent allowance from the USPTO exceeds our expectations," said Chris Bunka, chief executive officer of Lexaria. "This vastly expanded intellectual property protection will enable us to aggressively pursue new business opportunities in 2018 such as what could be the world's first nicotine edibles for the smokeless tobacco industry or enhanced products for NSAID-derived pain management, as well as in the rapidly growing cannabis market."
Lexaria's patented DehydraTech technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
Lexaria is presently investigating and will continue to pursue additional technologies that could deliver value to its growing portfolio of patented technologies.